RxDoctor Payments Data

Saira Nisar, MD

Internal Medicine · Fall River, MANPI 1114182680

Payments from drug & device makers

$986in general payments, 2019–2025

Across 12 payments — averaging $82.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$482
  • AstraZeneca$198
  • Integra Lifesciences Corporation$142
  • Abbott$90
  • Edwards Lifesciences$40
  • Avanir Pharmaceuticals, Inc.$22
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$986100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$986 in reported general payments places this provider in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$412,240
Medicare patients
769
Services billed
2,992

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban903$254,572
NuplazidPimavanserin Tartrate56$143,476
AustedoDeutetrabenazine19$52,732
XareltoRivaroxaban189$45,252
XifaxanRifaximin24$39,856
TrulicityDulaglutide55$30,195
NuedextaDextromethorphan Hbr/Quinidine42$29,522
GemtesaVibegron101$24,920
LinzessLinaclotide40$23,595
JardianceEmpagliflozin80$23,449
LokelmaSodium Zirconium Cyclosilicate36$19,809
RytaryCarbidopa/Levodopa16$17,336
DovatoDolutegravir Sodium/Lamivudine11$16,181
TradjentaLinagliptin64$16,046
Atorvastatin Calcium938$15,288

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$482$143,47656 claims
Avanir Pharmaceuticals, Inc.Nuedexta$22$29,52242 claims
AstraZenecaLokelma$198$19,80936 claims
Astellas Pharma US IncMyrbetriq$12$11,60654 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Fall River

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →